Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
Enveric Biosciences, Inc. (ENVB)
Company Research
Source: Business Wire
New patent marks Enveric’s 23rd issued U.S. patent for novel neuroplastogen molecules, increasing Enveric’s intellectual property footprint and supporting the potential for pipeline expansion CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of its 23rd patent from the United States Patent and Trademark Office (USPTO) for novel compounds within its neuroplastogenic patent estate, further expanding its intellectual property assets for the potential treatment of mental health disorders.The patent, U.S. Patent No. 12,428,408, titled, “Fused Heterocyclic Mescaline Derivatives,” covers a unique series of compounds, which are designed to target key serotonin receptors and drive neuroplasticity.“The issuance of this 23rd U.S. patent in Enveric’s neuroplastogenic patent estate d
Show less
Read more
Impact Snapshot
Event Time:
ENVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENVB alerts
High impacting Enveric Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ENVB
News
- Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”Business Wire
- Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug CandidatesBusiness Wire
- Enveric Biosciences GAAP EPS of -$10.81 [Seeking Alpha]Seeking Alpha
- Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results [Yahoo! Finance]Yahoo! Finance
- Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate ResultsBusiness Wire
ENVB
Sec Filings
- 12/5/25 - Form SCHEDULE
- 12/5/25 - Form S-3/A
- 11/14/25 - Form 10-Q
- ENVB's page on the SEC website